Trial Profile
A Randomized Controlled Study of Ferric Carboxymaltose versus Placebo in Patients with Heart Failure on Short Term Outcomes including quality of life, exercise tolerance, hemodynamic indices, serum BNP and ST2 levels
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 21 Sep 2016
Price :
$35
*
At a glance
- Drugs Ferric carboxymaltose (Primary)
- Indications Iron deficiency anaemia
- Focus Therapeutic Use
- 13 Sep 2016 Status changed from recruiting to discontinued.
- 17 Sep 2015 New trial record